Sumnuary High levels of IL-6 were found in 50% of 114 patients with pnrmary ovarian cancer. IL-6 sensitivity was lower than that of CA 125. and the combination of both assays did not increase the sensitivity of CA 125 alone. However, elevated IL-6 serum levels were correlated with a poor prognosis since patients with low IL-6 levels had a better survival than patients with high IL-6 levels (P = 0.0009). Multivariate analysis revealed that IL-6 positivity has an independent value.
Recent evidence has shown that IL-6. a multifunctional cytokine that regulates immune responses. acute-phase reactions and haematopoiesis. stimulates the proliferation of ovarian cancer cells in culture (Wu et al.. 1992) . Moreover. it has been reported (Watson et al.. 1990 : Berek et al.. 1991 ) that ascites of ovarian cancer patients contain high levels of IL-6 which correlate with disease status. Our previous report demonstrated that high serum IL-6 levels are a unique feature of ovarian cancer as compared with other gynaecological malignancies (Scambia et al.. 1994) and that. although IL-6 is less sensitive than CA 125 as a tumour marker for ovarian cancer. the production of IL-6 may be related to tumour aggressiveness.
The present study investigated the prognostic significance of serum IL-6 levels in 114 primary ovarian cancer patients. The correlation between IL-6 and the IL-6 soluble receptor (IL-6R) was also investigated. Patients (Serov et al., 1973) .
After surgery patients received cisplatin-containing regimens (Benedetti Panici et al., 1993) . Patients who initially had only an explorative laparotomy underwent a second laparotomy after chemotherapy, and a second cytoreduction was attempted. Venous blood samples for marker determinations were separated by centrifugation and aliquots were stored at -20°C until assay. IL-6 and IL-6R assays were performed using commercially available specific enzymatic immunoassays (RandD Systems Minneapolis, MN, USA). The detection threshold for IL-6 evaluation was 0.3 pg ml-'. The intra-assay variability for IL-6 and IL-6R analyses was 5-20% and 5-10% respectively. Since >95% of normal controls exhibited IL-6 serum levels within the range 1.9-6 pg ml-', 6 pg ml-' was used as the cut-off value. Normal control values of IL-6R ranged between 14.9 and 46.4 ng ml-' (mean value 26.5 ng ml-'). CA 125 was measured using a commercially available kit (CIS, Compagnie ORIS Industrie SA) and the upper limit of CA 125 for normal controls was 35 U ml-' (Scambia et al.. 1990 ).
The chi-square and Fisher's exact test were used to analvse the relationship between IL-6 serum values and tumour characteristics. All medians and life tables were computed using the product-limit estimate by Kaplan and Meier (1958) . and the curves were examined by the log-rank test (Mantel. 1966) . Multivariate analysis was performed with BMDP statistical software (Dixon, 1981) . A backward stepwise procedure was used to identify the major prognostic factors. Survival time was calculated from the date of diagnosis to the date of death. Table I shows the comparison of IL-6 distribution and positivity of IL-6 and CA 125 according to clinocopathological parameters. IL-6 positivity was not significantly related to stage, histology, grading or presence of ascites. However, the percentage of IL-6 positivity was significantly higher in patients with post-operative residual tumour > 2 cm as compared with patients with residual tumour ( 2 cm (P = 0.02). Although no linear correlation between IL-6 and CA 125 levels was found, the overall sensitivity was only slightly increased by the combination of IL-6 and CA 125. Ninety-two per cent of the serum samples showed a positive reaction in at least one test as compared with 87% for CA-125 alone (data not shown).
Results
Soluble IL-6R was also measured in 44 patients. Receptor levels were significantly increased as compared with normal controls (mean ± s.e.m 127 ± 1.1 range, 109.7-153.1. vs 26.5 ± 1.04, 14.9-43.4). No correlation between IL-6R and IL-6 serum levels was found (P = 0.27. P = 0. 15). Moreover. IL-6R was not related to any clinicopathological characteristics (data not shown).
Survival analysis of the overall patient population showed a shorter survival for patients with high IL-6 levels as compared with those patients presenting normal or low IL-6 values (P = 0.001 YOnly patients with stage III and IV disease are considered. *P = 0.02. Prognostic characterisation of patients with advanced ovarian cancer is still inadequate. Therefore, identification of variables correlating with tumour aggressiveness would contribute to the selection of therapy for individual patients. Our results show that elevated IL-6 serum levels in patients with primary epithelial ovarian cancer correlate with poor prognosis. Multivariate analysis showed that the association of high IL-6 levels with poor survival was independent of the other known prognostic factors such as stage and residual disease.
These results are consistent with previous data reported by Reibnegger et al. (1992) showing an association between IL-6 and disease progress in multiple myeloma. High serum IL-6 is also an adverse prognostic factor in renal cancer (Blay et al., 1992) and glioblastoma (Van Meir et al., 1990 (1989) showed that exogenous IL-6 increases the motility and decreases adherence of the breast carcinoma cell lines T47D and ZR75-1. suggesting that in vivo IL-6 may promote tumour metastasis and invasiveness. Alternatively, IL-6 could exert an adverse effect through a modulation of the antitumour response. Although in vitro IL-6 enhances the functions of cytotoxic T lymphocytes and natural killer cells and svnergises with IL-2 to increase the cytotoxic activity of peripheral blood T lymphocytes (Okada et al.. 1988) , high concentrations of inhibit the immune tumour response in a murine model (Tanner and Tosado, 1991) . In view of the high concentration of IL-6 found in ascites of ovarian cancer patients. this cytokine may play a similar role in this disease (Watson et al.. 1990 ).
In our series. increased IL-6 serum levels were accompanied by augmented IL-6R concentration. The regulation in vivo of the shedding of soluble IL-6Rs, the function and the significance of these soluble receptors in biological fluids are not currently understood. It has been suggested, however. that pathological conditions involving elevated levels of might also be associated with increased production of soluble IL-6Rs (Honda et al.. 1992 ). Accordingly, ovarian cancer patients exhibited increased serum levels of both IL-6 and soluble IL-6Rs.
The present report on a larger population confirms our previous finding that IL-6 is not a useful tumour marker for ovarian cancer. The sensitivity of IL-6 is lower than that of CA 125. Furthermore, combined IL-6 and CA 125 only slightly increased the overall sensitivity as compared with CA 125 alone.
This study, together with the in vitro results indicating that ovarian cancer cell proliferation and tumour angiogenesis are affected by IL-6 (Motro et al., 1990) , suggests new therapeutic strategies based on IL-6 interference by antisense oligonucleotides or monoclonal antibodies. In this regard, recent reports have shown that addition in culture of anti-IL-6 antibody and/or IL-6 mRNA antisense oligonucleotides inhibits the proliferation of carcinoma cell lines (Miki et al., 1989; Watson et al., 1993) .
In conclusion, data from the present study suggest that the assessment of serum IL-6 at the time of initial surgery may allow the identification of a subset of patients with a particularly poor prognosis. This aspect should be investigated in a larger clinical trial including other biological parameters in the multivariate analysis.
